Osilodrostat

an orally active aldosterone-synthase inhibitor

Also Known As:

(+)-Osilodrostat; 4-((5R)-6,7-dihydro-5H-pyrrolo(1,2-c)imidazol-5-yl)-3-fluoro-benzonitrile; Isturisa; LCI699; benzonitrile, 4-((5R)-6,7-dihydro-5H-pyrrolo(1,2-c)imidazol-5-yl)-3-fluoro-

Networked: 64 relevant articles (9 outcomes, 24 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - Osilodrostat: 64
  - Pyridines: 88
    - Osilodrostat: 64

Experts

1.	Fleseriu, Maria: 5 articles (01/2022 - 04/2014)
2.	Biller, Beverly M K: 4 articles (01/2022 - 04/2014)
3.	Castinetti, Frederic: 4 articles (01/2022 - 01/2021)
4.	Pivonello, Rosario: 4 articles (01/2022 - 04/2014)
5.	Tabarin, Antoine: 3 articles (01/2022 - 10/2020)
6.	Lacroix, André: 3 articles (01/2022 - 01/2020)
7.	Newell-Price, John: 3 articles (01/2022 - 01/2020)
8.	Shimatsu, Akira: 3 articles (08/2020 - 04/2016)
9.	Bertagna, Xavier: 3 articles (01/2020 - 04/2014)
10.	Amar, Laurence: 3 articles (03/2013 - 11/2010)

Related Diseases

1.	Pituitary ACTH Hypersecretion 01/01/2022 - "We aimed to evaluate the safety and efficacy of osilodrostat, a potent, orally available 11βhydroxylase inhibitor, compared with placebo in patients with Cushing disease. " 01/01/2023 - "Prospective studies have demonstrated the efficacy of osilodrostat in Cushing disease. " 01/01/2023 - "While phase II and III clinical studies have proven the clinical efficacy and tolerability of LCI699 for treating Cushing disease, few studies have attempted to fully assess the effects of LCI699 on adrenal steroidogenesis. " 01/01/2023 - "Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension." 12/01/2022 - "Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2)."
2.	Cushing Syndrome 10/01/2023 - "The novel potent steroidogenesis inhibitor osilodrostat can be used as first-line treatment for reducing hypercortisolism." 12/01/2022 - "Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples." 01/01/2022 - "According to the results of the LINC1, LINC2, and LINC3 studies and the preliminary findings of LINC4, osilodrostat offers an excellent efficacy in controlling hypercortisolism with a good tolerability. " 01/01/2019 - "Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study." 10/01/2023 - "Hypercortisolism was efficiently treated by osilodrostat with block-replace and then titration regimen. "
3.	Body Weight (Weight, Body) 08/01/2015 - "Mean body-weight gains from baseline to Week 13 were significantly lower in the pasireotide-alone and combined-treatment groups compared to controls, and were significantly higher in female rats receiving osilodrostat monotherapy. " 09/01/2021 - "Clinical trial data demonstrated that osilodrostat, by virtue of inhibiting 11-β hydroxylase, potently and rapidly decreased the 24-hour urinary free cortisol levels and sustained these reductions, with improved glycemia, blood pressure, body weight, and quality of life as well as lessened depression. "
4.	Hypertension (High Blood Pressure) 01/01/2015 - "We performed a meta-analysis of phase II randomized, controlled trials comparing the efficacy/safety of LCI699 with placebo in hypertension patients. " 01/01/2015 - "Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review." 01/01/2015 - "This study reviews the available data from randomized controlled trials on efficacy and safety of LCI699, a novel inhibitor of aldosterone synthase, as treatment of hypertension. " 03/01/2013 - "In this study, the efficacy and safety of the first-generation ASI LCI699 (0.25 mg twice daily, 1 mg 4 once daily, and 0.5 mg/1 mg twice daily) was compared with placebo and eplerenone (50 mg twice daily), in patients with resistant hypertension. " 10/01/2020 - "Osilodrostat was synthesized in a search for a drug that would inhibit the synthesis of aldosterone, with the aim to discover a new approach for treating hypertension. "
5.	Essential Hypertension 11/01/2011 - "We performed the first double-blind, randomized trial with LCI699 in patients with primary hypertension. " 01/01/2013 - "An 8-week placebo-controlled dose-response study on patients with Stage 1 and 2 essential hypertension reported an optimal decrease in BP with a dose of 1 mg LCI699 q.d., which had an antihypertensive effect similar to that of 50 mg b.i.d. "

Related Drugs and Biologics

1.	Osilodrostat
2.	Hydrocortisone (Cortisol)
3.	Metyrapone
4.	Mixed Function Oxygenases (Monooxygenases)
5.	Cytochrome P-450 CYP11B2 (CYP11B2)
6.	Adrenocorticotropic Hormone (ACTH)
7.	Steroid 11-beta-Hydroxylase (11 beta-Hydroxylase)
8.	Eplerenone (Inspra)
9.	Antihypertensive Agents (Antihypertensives)
10.	Aldosterone

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Off-Label Use
4.	Withholding Treatment
5.	Adrenalectomy